Lineage Cell Therapeutics (LCTX) Capital Expenditures Growth (3y) (2013 - 2026)
Powered by 
Analysis
Lineage Cell Therapeutics (LCTX) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 23.48% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 63.07% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -45.93% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -40.95% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 29.63% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 60.74% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.08% |
| 10 | Lineage Cell Therapeutics | 270.71 Mn | 213.99 Mn | 1.07 Mn | -28.65% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -28.65% |
| Mar 31, 2026 | -28.06% |
| Dec 31, 2025 | 199.77% |
| Sep 30, 2025 | -65.25% |
| Jun 30, 2025 | -47.55% |
| Mar 31, 2025 | 28.23% |
| Dec 31, 2024 | 35.72% |
| Sep 30, 2024 | 27.53% |
| Jun 30, 2024 | -27.09% |
| Mar 31, 2024 | 51.17% |
| Dec 31, 2023 | 55.93% |
| Sep 30, 2023 | 79.58% |
| Jun 30, 2023 | 249.43% |
| Mar 31, 2023 | 165.90% |
| Dec 31, 2022 | -62.43% |
| Sep 30, 2022 | 60.63% |
| Jun 30, 2022 | -20.77% |
| Mar 31, 2022 | -35.19% |
| Dec 31, 2021 | -31.79% |
| Sep 30, 2021 | -30.66% |